Greenwich Lifesciences Inc (GLSI) Stock Price, Quote & News

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy...

Industry: Biotechnology

Sector: Healthcare

Phone: 832-819-3232

Website: greenwichlifesciences.com

Address:

Building 14, 3992 Bluebonnet Dr., Stafford, United States

Waterwing Jun. 25 at 4:22 AM

$GLSI

1 · Reply

ATXAMPEREStrategies Jun. 25 at 1:57 AM

$GLSI several folks complaining about the equity drifting….if you want to do something about it stop lending out your shares. If you are complaining or disappointed in the price action and you are lending out your shares. Blame yourself. Not the company.

1 · Reply

55X_ROI_Q1_2026 Jun. 25 at 1:23 AM

$GLSI @Rolltide2020 thanks for the AI SLOP fact - 6 patients who relapsed early were Censored --- --- Snehel / his family . his family trusts, and insiders cashed in HUGE $70 some million - and all the "insider buys" are minuscule, by comparison, and catnip to inch thick mile wide retail lemmings who don't have a clue... --- what happened to your BS about there only being 1 patel? there are 3 - plus the 6 Family Trusts --- 2017 at the earliest for any news --- done wasting my time here, with shit i forgot 5 years ago ... gl2u Meanwhile SLS has IMMINENT PHASE 3 RESULTS for a Much more advanced Agent in a very immunogenic WT1+ target.

0 · Reply

55X_ROI_Q1_2026 Jun. 25 at 1:14 AM

$SLS $ABVX bumping around $5 and change to a high of $148 based on its P3 Trial Data - that everyone knew was due ... +3,000 ROI --- very Similar to what is about to happen here. $GLSI

1 · Reply

55X_ROI_Q1_2026 Jun. 24 at 10:11 PM

$SLS $GLSI Phase 3 Registrational Results - for Gps, an AML Remission Maintenance Immunotherapy, Now Truly Imminent.

0 · Reply

Rolltide2020 Jun. 24 at 9:58 PM

$GLSI Your scorecard.

0 · Reply

Spiteful4Life Jun. 24 at 9:13 PM

$GLSI The lack of PR or more under buying is feeding the bull trough.

0 · Reply

55X_ROI_Q1_2026 Jun. 24 at 8:46 PM

$GLSI do some basic due diligence https://www.sec.gov/Archives/edgar/data/1806920/000121390020029374/xslF345X03/ownership.xml snehel and his family trust bought gp2 from norwell inc for 4m after the galena fail, repackaged the trial data / and sold $77M ish in the +3,000% insanity. again, intracellular, gp2 maybe better than neuvax, but for sure isn’t anywhere as effective as newer heteroclitic vaccines that have proven durability /cd4 t cell activation.

2 · Reply

55X_ROI_Q1_2026 Jun. 24 at 8:30 PM

$GLSI @Rolltide2020 not sure if you are ignorant or lying. Snehel's FAMILY TRUST Sold $77M -- its in the edgar data base. keep your head in the sand / or keep lying to con. the 100% DFS P2 Data that Snehel repackaged and republished was ALREADY PUBLIC Knowledge for OVER A YEAR - had been published for over a YEAR before he scrubbed 6 patients and called it 100% DFS. There were 3 Peptide vaccines developed by Dr. Peoples, Neuvax Phase 3 Failed mostly due to the lack of durable T Cell / cd4 Antigen Express owns 1 ... development halted and Snehel bought GP2 from Norwell for $4M / then Ipo'd it for $5M / he and his family trust bought $3.5M of the public float. its all public

2 · Reply

Team_Zissou Jun. 24 at 8:07 PM

$GLSI This stock is a perfect vehicle to hold a core position and trade around it. I consider my full position as roughly 4,000 shares. When we get down in the $22 range, I top off to around 4,000. When we get north of $26, I sell half my position. Rinse and repeat. It’s been a profitable way to maintain exposure to the stock without feeling like I’m missing out on other opportunities. Your mileage may vary.

0 · Reply

Greenwich LifeSciences presents FLAMINGO-01 data at ASCO

Jun 1, 2026, 8:15 AM EDT - 23 days ago

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

2026-06-01T10:21:46.000Z - 23 days ago

Greenwich LifeSciences provides update on 10-K filing

Jun 1, 2026, 6:00 AM EDT - 23 days ago

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

May 22, 2026, 4:30 PM EDT - 4 weeks ago

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

2026-04-30T10:11:17.000Z - 7 weeks ago

Greenwich LifeSciences says Form 10-K ‘still being audited’

Apr 23, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

2026-04-22T21:05:16.000Z - 2 months ago

Greenwich LifeSciences receives noncompliance notification from Nasdaq

Apr 22, 2026, 5:00 PM EDT - 2 months ago

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

2026-04-20T10:17:19.000Z - 2 months ago

Greenwich LifeSciences presents Flamingo-01 Phase 3 results from AACR 2026

Apr 20, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

2026-04-14T10:21:37.000Z - 2 months ago

Greenwich LifeSciences reports cash balance of $10.5M as of March 31

Apr 14, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update on Financing Strategy

2026-04-07T10:06:43.000Z - 2 months ago

Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01

Apr 7, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

2026-03-19T10:12:27.000Z - 3 months ago

Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial

Mar 19, 2026, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

2026-03-18T10:11:20.000Z - 3 months ago

Greenwich LifeSciences provides update on presentations at AACR Meeting 2026

Mar 18, 2026, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

2026-03-17T10:21:32.000Z - 3 months ago

Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial

Mar 17, 2026, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

2026-03-16T10:32:26.000Z - 3 months ago

Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01

Mar 16, 2026, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

2026-03-03T11:05:58.000Z - 4 months ago

Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial

Mar 3, 2026, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Feb 24, 2026, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

2026-01-27T11:11:03.000Z - 5 months ago

Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial

Jan 27, 2026, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

2026-01-22T11:21:40.000Z - 5 months ago

Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA

Jan 22, 2026, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

2025-12-30T11:10:33.000Z - 6 months ago

Greenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright

2025-12-29T11:15:15.000Z - 6 months ago

Greenwich LifeSciences extends lock-up of directors, officers to September 30

Dec 29, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

2025-12-22T11:21:11.000Z - 6 months ago

Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters

Dec 22, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

2025-12-15T11:16:50.000Z - 6 months ago

Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm

Dec 15, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

2025-12-08T11:10:12.000Z - 7 months ago

Greenwich LifeSciences: Enrollment complete in open label arm oFLAMINGO-01 trial

Dec 8, 2025, 6:00 AM EST - 7 months ago

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Dec 3, 2025, 6:00 AM EST - 7 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Oct 9, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Oct 2, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Sep 30, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 18, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 10, 2025, 6:00 AM EDT - 10 months ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Aug 20, 2025, 9:25 AM EDT - 11 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 19, 2025, 6:00 AM EDT - 11 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 13, 2025, 6:00 AM EDT - 11 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 11, 2025, 6:00 AM EDT - 11 months ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Mar 27, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 17, 2025, 6:45 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Jan 29, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 27, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 23, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 22, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 14, 2025, 6:15 AM EST - 1 year ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events

Aug 1, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Jun 26, 2024, 7:33 AM EDT - 2 years ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Mar 13, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 12, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Feb 27, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 22, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Waterwing Jun. 25 at 4:22 AM

$GLSI

1 · Reply

ATXAMPEREStrategies Jun. 25 at 1:57 AM

1 · Reply

55X_ROI_Q1_2026 Jun. 25 at 1:23 AM

0 · Reply

55X_ROI_Q1_2026 Jun. 25 at 1:14 AM

$SLS $ABVX bumping around $5 and change to a high of $148 based on its P3 Trial Data - that everyone knew was due ... +3,000 ROI --- very Similar to what is about to happen here. $GLSI

1 · Reply

55X_ROI_Q1_2026 Jun. 24 at 10:11 PM

$SLS $GLSI Phase 3 Registrational Results - for Gps, an AML Remission Maintenance Immunotherapy, Now Truly Imminent.

0 · Reply

Rolltide2020 Jun. 24 at 9:58 PM

$GLSI Your scorecard.

0 · Reply

Spiteful4Life Jun. 24 at 9:13 PM

$GLSI The lack of PR or more under buying is feeding the bull trough.

0 · Reply

55X_ROI_Q1_2026 Jun. 24 at 8:46 PM

2 · Reply

55X_ROI_Q1_2026 Jun. 24 at 8:30 PM

2 · Reply

Team_Zissou Jun. 24 at 8:07 PM

0 · Reply

LIGator Jun. 24 at 7:25 PM

$GLSI I see the 🐻 are out in full force today. What’s wrong 🩳 paying 120% for the past month is forcing you into desperation mode. I do appreciate the effort but it is not working. I bought 300 more shares.

3 · Reply

Rolltide2020 Jun. 24 at 6:52 PM

$GLSI 1.) Snehal and family did not cash in. There was an Amit Patel who was an investor, but not related to Snehal Patel. Patel is #1 or #2 most common last name in India. If Snehal Patel was John Smith and Amit Patel was James Smith, this shit wouldn't keep getting brought up falsely. 2.) This guy reading out of the White Diamond bullshit playbook. If there had been improper exclusion of recurrence events: it would typically show up in FDA correspondence DSMB concerns or peer-reviewed critique or audit findings There is no public evidence of regulatory action or validated audit finding stating GLSI improperly excluded recurrence events from Phase 2 analysis. 3.) Galena and GLSI are scientifically related programs, not identical ones Galena’s Phase 3 issue was not “lack of any immune effect,” but: inconsistent translation into durable clinical benefit in the full population GLSI is attempting to fix: patient selection immune response consistency statistical structure

2 · Reply

Hinthint Jun. 24 at 6:45 PM

$GLSI With each and every conference that comes and goes, folks are consistently hoping and quoting but it usually ends up as a big nothing burger. The bottom line is that we won't hear any good (or bad) news for another year or two. When it happens it will happen and no sooner. This is a lottery ticket that I will buy... just not right now. I'm in no rush.

2 · Reply

55X_ROI_Q1_2026 Jun. 24 at 6:42 PM

$GLSI it makes absolutely ZERO Financial Sense for anyone to have a Penny Invested here - waiting for over a year for the P3 - for the Neuvax Sister drug to report - while GPS - a much improved Heteroclitic, Non HLA restricted Immunotherapy is about to report - imminent Phase 3 Results for AML Remission Maintenance. the Kickers; the IDMC UNBLINDED ACTUAL Phase 3 MOS AND IR data from the INTERIM ANALYSIS - that told Every one GPS is Golden. - Market Evidence: SLS Mcap Up 1,200% Since Then, Share Price up 900%, Institutional Investment up 500%, CASH on HAND up 1,200% --- - BAT for Control Arm Patients - Failed 3 Large Phase 3 Trials, including 2 for AML REMISSION Maintenance. just saying - this dead meat money could 10x or more in SLS - ANY DAY NOW. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

2 · Reply

Whiskeyunderthebed Jun. 24 at 5:08 PM

$GLSI XBI is hitting a 52 week high again today and is pulling most small cap Bios up.... this is disconnected.

0 · Reply

WolfSK Jun. 24 at 3:56 PM

$GLSI Days like today are very frustrating but I just try to focus on the positives. The biggest positive, in my view, is that after all this time, the core thesis appears largely unchanged. Infact the story is getting better: • Trial still running. • Enrollment still progressing. • FDA supportive of non-HLA. • Manufacturing progressing. • Cash position confirmed. • No major safety signal. • No futility stop. The market is frustrated because it wants the next catalyst. But frustration and a broken thesis are not the same thing. The next meaningful update is likely to be far more important than the recent drift in the share price. Hopefully it will take us to a new trading range in the 30’s or higher. GLA

3 · Reply

HiLowGo Jun. 24 at 3:42 PM

$GLSI Listen, Snehal some news tomorrow would be great. Just give us a little bit of something. The silence is scary to the people!!

0 · Reply

mshah1615 Jun. 24 at 3:35 PM

$GLSI Not Good Day today

0 · Reply

Rolltide2020 Jun. 24 at 2:50 PM

$GLSI 18:51 mark of Noble Conference video, Snehal talks about enrolling through interim and allowing the DSMB to advise on continuing enrolling. Chat's take (FWIW): The key phrase is not "continue enrolling through interim." Many companies do that. The more important phrase is "allow the DSMB to advise whether they should continue enrolling or stop enrolling." That acknowledges the possibility that the interim could be meaningful enough that enrollment strategy changes afterward. Companies don't usually highlight that possibility unless they view it as a realistic outcome.

2 · Reply

mshah1615 Jun. 24 at 1:37 PM

$GLSI 2000 trade went at 23.4999

1 · Reply

mshah1615 Jun. 24 at 12:41 PM

$GLSI Anything Ftom BIO conference ? Now wait & Watch game from SP

0 · Reply

Machiavellia Jun. 24 at 9:10 AM

$GLSI Snehal casually dropping mid-interview about a change to the interim and then going radio silent... We could do with some communication - usually I'm a big advocate for the way he keeps shareholders in the loop. Hopefully there are good things that he simply can't talk about yet but leaving markets to fill in the blanks doesn't sit well.

1 · Reply

Market Cap	338.03M
Revenue (ttm)	0.00
Net Income (ttm)	-19.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	135,500
Avg Vol	135,346
Day's Range	N/A - N/A
Shares Out	14.68M
Stochastic %K	31%
Beta	1.40
Analysts	Strong Sell
Price Target	$47.50